Microscope image of human cancer. Black dots on right side are lymphocytes being stopped by CAFs.
A study led by the University of Southampton, funded by Cancer Research UK, has shown a new drug – originally developed to tackle the scarring of organ tissue – could help to significantly improve the success rate of cancer immunotherapy treatment.
Scientists have shown in mouse cancers, that GKT137831 (Setanaxib) can help break down the ‘barrier’ which makes many cancerous tumours resistant to immunotherapy drugs. GKT137831 is a drug currently undergoing clinical trials for treatment of organ fibrosis.
The team’s findings are published in the journal Cancer Research, a journal of the American Association for Cancer Research.
Immunotherapy treatment harnesses the power of the body’s own immune system to fight cancer. Its success depends on ‘killer’ lymphocytes penetrating into a tumour to combat malignant cells. However, most patients fail to respond, often because the lymphocytes are blocked at the edge of the tumour, preventing their attack. The scientists behind this latest study believe they have found why this happens and identified a way to overcome it – potentially improving immunotherapy treatment for many patients with different types of cancer.
The team found that normal cells called cancer-associated fibroblasts (CAF) are hijacked by cancer cells to protect them from immune attack. Fibroblasts are healthy cells that normally maintain the structure of tissues, but when they are corrupted by cancer cells, they become CAFs and shield tumours from lymphocyte attack and stop immunotherapy from working effectively. A significant proportion of many solid cancers are CAF-rich and associated with poor survival, including more than 50 percent of cases of head and neck, esophageal, colorectal and pancreatic cancers.
Previously, the group had identified that CAF formation depends on an enzyme called NOX4. In this study, they found that blocking NOX4 in mouse cancers, either genetically or with the drug GKT137831, could prevent and reverse CAF formation, allowing lymphocytes to infiltrate tumours and kill cancer cells*. Combining immunotherapies with GKT137831 was effective in treating tumours that were previously resistant, significantly improving survival**.
The findings could form the basis for making cancers respond better to existing immunotherapy drugs and demonstrate the potential for greatly improved clinical outcomes in a significant number of cancers. Cancer Research UK is currently funding the Southampton scientists to see if this approach improves immunotherapy in breast cancer.
Study author Professor Gareth Thomas, of the University of Southampton’s Centre for Cancer Immunology, comments: “Immunotherapy for cancer has been a very exciting development, but still doesn’t work in most patients. Our results suggest that in many cases, treatment resistance is caused by CAF, and we think this can be overcome by targeting NOX4. GKT137831 hasn’t yet been tested on cancer patients, but we hope may give immunotherapy drugs a much better chance of fighting cancer cells effectively; this technique could hugely improve the success rate of cancer immunotherapy.”
Liz Allaway, from Cancer Research UK says: “Immunotherapy is a promising cancer treatment that boosts the power of the body’s immune system against cancer, but unfortunately it doesn’t work for everyone. This exciting study showed that a drug, currently being tested for the treatment of another disease could make tumours in the lab more sensitive to immunotherapy. The next step would be to see if the drug has the same effect in people, which would open up immunotherapy as a treatment option for more people with cancer.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- FDA Grants Fast Track Designation to GEN-1 for Advanced Ovarian Canceron February 23, 2021 at 12:36 pm
A novel DNA-mediated interleukin-12 immunotherapy, GEN-1, had been granted a Fast Track designation by the FDA for the treatment of advanced ovarian cancer.
- The unveiling of a novel mechanism of resistance to immunotherapy targeting HER2on February 23, 2021 at 10:08 am
Immunotherapy continues to show exciting promise in more effectively combating several tumor types. Many current strategies focus on ensuring the efficient delivery of active cytotoxic cells directly ...
- Extensive Demand for T-Cell Adoptive Immunotherapy Rising with Growing Prevalence of Canceron February 23, 2021 at 5:30 am
In the breast cancer therapy market, the rise in the prevalence of cancer, has propelled the T-cell therapy market over the last few years and it is projected to continue to do so for several years to ...
- Immunotherapy Granted FDA Fast Track Designation in Advanced Ovarian Canceron February 23, 2021 at 5:25 am
The FDA has granted a fast track designation to the DNA-mediated interleukin-12 immunotherapy GEN-1 for use in the treatment of patients with advanced ovarian cancer.
- Regeneron wins FDA OK in lung cancer for immunotherapy rival to Merck's Keytrudaon February 22, 2021 at 3:39 pm
The approval of Libtayo in first-line lung cancer will pit Regeneron's drug, developed in partnership with Sanofi, against Merck's top-selling immunotherapy Keytruda.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Genkyotex Announces 2020 Annual Financial Results and Provides Corporate Updateon February 18, 2021 at 3:23 pm
Genkyotex (Paris:GKTX) (Brussels:GKTX) (Euronext Paris & Brussels: FR0013399474 – GKTX), a biopharmaceutical company and the lead ...
- Genkyotex Announces 2020 Annual Financial Results and Provides Corporate Updateon February 18, 2021 at 10:57 am
Phase 1 trial with setanaxib at higher doses: in January 2021, the Company reported positive data from its Phase 1 clinical trial to evaluate the safety and pharmacokinetics of setanaxib at ...
- Calliditas announces clinical development plan for setanaxib and comments on data from Part A of NefIgArd study at today´s R&D Dayon January 20, 2021 at 12:29 am
STOCKHOLM , Jan. 20, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX) (NASDAQ - CALT) today announced it will provide information on the near-term clinical ...
- Calliditas announces clinical development plan for setanaxib and comments on data from Part A of NefIgArd study at today´s R&D Dayon January 19, 2021 at 11:20 pm
In Q4 of 2020 Calliditas acquired a controlling stake in Genkyotex, which has been developing a first in class platform for NOX inhibition and where the lead compound, setanaxib has been tested in ...
- Calliditas announces clinical development plan for setanaxib and comments on data from Part A of NefIgArd study at today's R&D Dayon January 19, 2021 at 6:13 pm
STOCKHOLM, Jan. 20, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX) (NASDAQ - CALT) today announced it will provide information on the near-term clinical ...